Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial

医学 美洛昔康 安慰剂 强直性脊柱炎 吡罗昔康 内科学 随机对照试验 药品 麻醉 药理学 病理 替代医学
作者
Maxime Dougados
出处
期刊:British journal of rheumatology 卷期号:38 (3): 235-244 被引量:158
标识
DOI:10.1093/rheumatology/38.3.235
摘要

OBJECTIVE: To consider the relevance of the duration of a clinical trial in ankylosing spondylitis: long-term (i.e. 1 yr) vs short-term (i.e. 6 weeks) assessment of a non-steroidal anti-inflammatory drug (NSAID)-placebo controlled study. METHODS: The design was a prospective, multicentre, double-blind, placebo-controlled study of 6 weeks duration with a 12 months double-blind extension. Study drugs were placebo (n = 121) or active NSAID (n = 352). A decrease of at least 50% in pain and/or global assessment and/or functional impairment during the study defined the response to treatment. The percentage of patients discontinuing the study drug over time (life table analysis) permitted the evaluation of both the efficacy and toxicity. RESULTS: Among the 473 recruited patients, the percentage of responders was similar at 1 yr and week 6 with a highly statistically significant difference in favour of the active NSAID groups when compared to placebo (at 1 yr, 17% in the placebo group vs 37, 50 and 43% in the piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg, respectively, for the patient's overall assessment) without any statistically significant difference between the three active groups. However, evaluation of the patients discontinuing the study drug during the 1 yr of the study permitted the detection of a statistically significant difference between the active NSAID groups. A lower percentage of patients taking meloxicam 22.5 mg had to discontinue the study drug when compared to either meloxicam 15 mg or piroxicam 20 mg (37% vs 53% and 53%, respectively, P < 0.05). By 52 weeks, drug-related upper gastrointestinal adverse events occurred in 13, 32, 20 and 18% in the placebo, piroxicam 20 mg, meloxicam 15 mg and meloxicam 22.5 mg groups, respectively. Some of the adverse events occurred only after week 6. CONCLUSION: This study suggests that a 1 yr trial might be of optimum value compared to a 6 week assessment in order to define better the efficacy and tolerability of NSAIDs in ankylosing spondylitis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
Polarlicht完成签到,获得积分10
3秒前
媛媛完成签到,获得积分10
3秒前
傲娇颖完成签到,获得积分10
5秒前
ShellyMaya完成签到 ,获得积分10
6秒前
7秒前
一只大憨憨猫完成签到,获得积分10
7秒前
JJ完成签到,获得积分10
7秒前
DrW完成签到,获得积分10
7秒前
隐形曼青应助yue采纳,获得10
8秒前
ccyy完成签到 ,获得积分10
8秒前
NexusExplorer应助腾腾腾采纳,获得10
9秒前
宿帅帅完成签到,获得积分10
10秒前
10秒前
Ningxin完成签到,获得积分10
10秒前
HHEHK发布了新的文献求助10
10秒前
柚子完成签到 ,获得积分10
10秒前
雨辰完成签到,获得积分10
12秒前
宿帅帅发布了新的文献求助10
12秒前
量子星尘发布了新的文献求助10
15秒前
15秒前
熠熠完成签到,获得积分10
15秒前
16秒前
zxzb完成签到,获得积分10
18秒前
苹果萧完成签到 ,获得积分10
21秒前
宋江他大表哥完成签到,获得积分10
21秒前
able发布了新的文献求助10
21秒前
王先生完成签到 ,获得积分10
22秒前
H.发布了新的文献求助10
22秒前
luoluo完成签到,获得积分10
23秒前
23秒前
高分子完成签到,获得积分10
23秒前
yian发布了新的文献求助10
24秒前
yar应助体贴凌柏采纳,获得10
25秒前
自由的雪一完成签到,获得积分10
25秒前
Ava应助李振博采纳,获得200
25秒前
JW发布了新的文献求助10
26秒前
无限的千凝完成签到 ,获得积分10
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038303
求助须知:如何正确求助?哪些是违规求助? 3576013
关于积分的说明 11374210
捐赠科研通 3305780
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029